ATB1071 是一种可透过血脑屏障且口服有效的 p62/SQSTM1 激活剂,可结合 p62-ZZ 结构域,促进依赖 PB1 的 p62 自聚合,并激活 p62 介导的线粒体自噬 (mitophagy),可用于利氏综合征及脑缺血再灌注损伤的相关研究。
产品编号: MS-G45037 CAS No.: 2921556-65-0 分子式: C25H27F2NO4 分子量: 443.48
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

ATB1071 是一种可透过血脑屏障且口服有效的 p62/SQSTM1 激活剂,可结合 p62-ZZ 结构域,促进依赖 PB1 的 p62 自聚合,并激活 p62 介导的线粒体自噬 (mitophagy),可用于利氏综合征及脑缺血再灌注损伤的相关研究。

生物实验数据

生物活性 ATB1071 is a blood-brain barrier-permeable and orally effective p62/SQSTM1 activator that binds to the p62-ZZ domain, promotes PB1-dependent p62 self-aggregation, and activates p62-mediated mitophagy, making it suitable for research on Leigh syndrome and cerebral ischemia-reperfusion injury.
体外研究
(In Vitro)

ATB1071 (1 mM;2 小时) 结合 p62-ZZ 结构域以在 HeLa 细胞裂解物中促进依赖 PB1 的 p62 寡聚化。
ATB1071 可在 SH-SY5Y 细胞中激活依赖 p62 的选择性自噬,且不会引发经典的 AMPK 激活或 mTOR 抑制。
ATB1071 (2.5-10 μM) 可在 SH-SY5Y 细胞的线粒体应激条件下,选择性诱导依赖 p62 的、自噬溶酶体介导的受损线粒体清除,且呈现剂量依赖性活性。
ATB1071 在 Rotenone (MS-D42728) 诱导的应激条件下,通过不依赖 Parkin 的途径诱导 mt-mKeima HeLa 细胞发生线粒体自噬,并在 CCCP (MS-F33925) 诱导的应激条件下增强 Parkin 介导的线粒体自噬。
ATB1071 可激活线粒体自噬并恢复 NDUFS4 敲低的 SH-SY5Y 细胞中的线粒体生物能量功能,逆转线粒体膜电位 (MMP) 去极化、活性氧 (ROS) 升高及 ATP 缺乏。
ATB1071 (2-5 μM;8-24 小时) 可增强 HEK293T 细胞中 p62 与 NIPSNAP1 的相互作用,在线粒体应激条件下该作用尤为显著,其机制依赖于 p62 的 ZZ/PB1 轴。

体内研究
(In Vivo)

ATB1071 (10 mg/kg;腹腔注射;隔日给药;共 40 天) 可激活脑内 p62 相关的线粒体自噬,减轻神经炎症,并在 Leigh 综合征小鼠模型中改善神经肌肉功能与生存状态。
ATB1071 (10 mg/kg;腹腔注射;大脑中动脉闭塞手术后 0、3、24 及 48 小时给药) 可提供强效神经保护作用,并主要通过 EBP1 依赖的线粒体自噬恢复脑缺血再灌注损伤后的神经功能。
ATB1071 (10 mg/kg;腹腔注射;大脑中动脉闭塞术后 0、3、24 及 48 小时) 可通过重新导入 EBP1 恢复其介导的线粒体自噬,从而在 Ebp1 缺陷小鼠脑缺血再灌注损伤后增强神经保护作用并促进功能恢复。
ATB1071 (口服;持续一周每天给药或持续两周,一周三次给药) 在 ICR 小鼠和大鼠中的 NOAEL 至少为 30 mg/kg 和 300 mg/kg。

Animal Model: B6.129S4-Ndufs4m1.1Rpa/J mice (Ndufs4-/-; starting at postnatal day 10); wild-type/heterozygous control mice (starting at postnatal day 10)
Dosage: 10 mg/kg
Administration: i.p.; every other day; 40 days
Result: Increased TOM20+LC3+ proximity ligation assay puncta in the deep cerebellar nuclei and olfactory bulb of Ndufs4-/- mice.
Elevated p62 levels by ~1.8-fold and its oligomeric/aggregated species by ~2.4-fold in the brain mitochondrial fraction.
Reduced GFAP+ astrocytes and Iba1+ microglia.
Lowered expression of inflammation-associated genes (Cd14, Il-1β, S100a8).
Extended median survival by ~31% and maximal lifespan by ~64% relative to vehicle-treated Ndufs4-/- mice.
Improved forelimb grip strength by ~34% at postnatal day 40.
Increased rotarod latency to fall by ~3-fold at postnatal day 50.
Delayed the onset of clasping/twisting by ~12%.
Reduced skin inflammation-associated hair loss severity scores from 2 to 1.22 at postnatal day 20.
Animal Model: Pa2g4flox/flox mice (control; aged 6-8 weeks); CamK2-Cre;Pa2g4flox/flox mice (neuron-specific Ebp1 knockout, Ebp1 CKO; aged 6-8 weeks)
Dosage: 10 mg/kg
Administration: i.p.; at 0, 3, 24, and 48 hours post-MCAO
Result: Decreased TOM20 levels, increased p62 and LC3-II levels, and enhanced recruitment of LC3+ phagophores to TOM20+ mitochondria in the hippocampus of control MCAO mice.
Reduced infarct volume by ~85% in control MCAO mice.
Lowered neuronal death in the CA1 region by ~91% in control MCAO mice.
Increased rotarod latency to fall from 54.7 to 207.4 seconds in control MCAO mice.
Enhanced four-limb grip strength by ~1.3-fold and forelimb grip strength by ~1.6-fold in control MCAO mice.
Increased total open-field travel distance from 1919 to 2579 cm in control MCAO mice.
Raised Y-maze spontaneous alternation rate from 53% to 83% in control MCAO mice.
Blunted effects in Ebp1 CKO mice, with only ~46% infarct volume reduction, ~40% neuronal death reduction, and no significant improvements in motor, behavioral, or cognitive functions.
Animal Model: CamK2-Cre;Pa2g4flox/flox mice (neuron-specific Ebp1 knockout, Ebp1 CKO; aged 6-8 weeks)
Dosage: 10 mg/kg
Administration: i.p.; at 0, 3, 24, and 48 hours post-MCAO
Result: Restored ATB1071-induced mitophagy in Ebp1 CKO mice via EBP1 reintroduction, as shown by increased LC3 and p62 levels and enhanced mitochondrial localization of LC3 in the hippocampus.
Reduced infarct volume by ~67% (vs ~52% in mock-expressing mice).
Lowered neuronal death by ~86% relative to the mock group.
Improved rotarod performance by ~2.2-fold.
Increased four-limb grip strength by ~1.5-fold and forelimb grip strength by ~1.5-fold.
Increased ambulatory activity by ~1.5-fold.
Improved working memory by ~33% compared with mock-expressing Ebp1 CKO mice.

化学信息

分子量 443.48
分子式 C25H27F2NO4
CAS No. 2921556-65-0

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础